Industry Watch [to 5 November 2016]
:: Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China
Prevenar 13® is Approved to Help Protect Infants and Children Aged Six Weeks to Fifteen Months from Invasive Pneumococcal Disease
November 02, 2016
NEW YORK–(BUSINESS WIRE)–Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its pneumococcal 13-valent conjugate vaccine, Prevenar 13®, in China for active immunization for the prevention of invasive diseases (including bacteremic pneumonia, meningitis, septicemia, and bacteremia) caused by Streptococcus pneumoniae (S. Pneumoniae) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in infants and children aged 6 weeks to 15 months. S. pneumoniae is the most common cause of invasive disease as well as pneumonia and upper respiratory tract infections…
:: Takeda Donates 1 Billion Yen as an Exclusive Partner to the United Nations Foundation for “Global Measles Vaccination for Children” Program
– Aiming at vaccinating 5.4 million children in approximately 40 developing countries –
November 01, 2016
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited today announced that Takeda will exclusively support “Global Measles Vaccination for Children” by the United Nations Foundation’s Shot@Life campaign. The initiative aims to provide measles vaccination to at least 5.4 million children in approximately 40 developing countries in Africa, Asia, and Latin America over 10 years. We have donated one billion yen to the United Nations Foundation to implement the program…
:: 17th DCVMN Annual General Meeting – Corporate members elected the new members of the DCVMN Executive Committee and the new elected President is Ms. Mahima Datla, CEO of Biological E, from India.
PhRMA [to 5 November 2016]
New report highlights need to speed patent examination
Mark Grayson November 2, 2016
The Center for the Protection of Intellectual Property released a new report, “The Long Wait for Innovation: The Global Patent Pendency Problem,” documenting the growing global challenge of patent pendency – the length of time a patent application is left pending while under review.
The report found that while every country faces its own unique problems related to the backlog of patent applications, new trends and leaders in patent innovation have emerged. For example, countries such as Korea are strengthening commitments to patent processing and currently experiencing pendency of 2.8 years compared to 6.3 years in India.
Yet several countries are still falling behind the pendency curve. In countries such as Thailand and Brazil, the average time from patent application to approval is 10 years or more. This problem not only affects developing countries, but is a looming challenge in the United States and Europe, both of which are mature economies, governments and bureaucracies…